AdaptHealth (AHCO) Q2 2023: Sleep and Respiratory Revenue Up 15%, Offsetting Diabetes Headwinds
Sleep and respiratory segments delivered double-digit growth, reinforcing AdaptHealth’s core market leadership even as diabetes rebounded only modestly. Strategic execution on cost savings and digital process improvements drove margin expansion and improved cash flow, while the Humana partnership signals a shift toward value-based care at national scale. Investors should focus on execution in diabetes, the impact of payer mix, and the ramp of the Humana contract in the back half of 2023.
Summary
- Margin Expansion Through Cost Controls: Technology-enabled efficiency and disciplined cost management lifted margins despite mixed segment growth.
- Core Business Outperformance: Sleep and respiratory lines delivered robust growth, offsetting diabetes and commercial channel softness.
- Strategic Partnerships Drive Next Leg: Humana value-based contract implementation is a key growth and operational test for the coming quarters.
Business Overview
AdaptHealth is a leading U.S. provider of home medical equipment (HME, durable medical devices for home use), supplies, and connected health solutions for chronic care patients. The company serves approximately 4 million patients through three major segments: Sleep (primarily PAP equipment for sleep apnea), Respiratory (oxygen and ventilation support), and Diabetes (continuous glucose monitors, or CGMs, and insulin pumps). Revenue is generated through device sales, resupply, and service contracts—primarily reimbursed by Medicare, Medicaid, and commercial insurers. AdaptHealth’s business model increasingly leverages data connectivity and value-based payer partnerships to drive growth and operational efficiency.
Performance Analysis
Q2 results were defined by the continued strength in AdaptHealth’s core sleep and respiratory segments, which together comprise over half of total revenue and delivered combined growth of 15% year over year. Sleep revenue climbed 16%, propelled by a 41% increase in PAP patient census and double-digit resupply order growth. Respiratory revenue rose 13%—its best patient acquisition quarter since late 2021—driven by normalized patient setup trends and stabilization in oxygen therapy durations.
Diabetes revenue improved modestly, up 2% year over year, reflecting a rebound from Q1 but still lagging the broader market’s expansion for CGMs and pumps. The company’s government payer mix in diabetes climbed to 77%, reflecting a deliberate pivot to this higher-growth, inflation-resistant channel, but commercial business remained pressured. Cost control and digital process initiatives, including e-prescribe adoption and warehouse automation, supported a 14% increase in adjusted EBITDA and a 100 basis point margin improvement. Free cash flow and DSO (days sales outstanding) metrics also trended positively, underpinned by tighter revenue cycle management.
- Sleep and Respiratory Outperformance: These segments drove the majority of margin improvement and market share gains, with supply chain normalization and operational investments now yielding tangible results.
- Diabetes Channel Shift: Growth in government census offset commercial softness, but pump headwinds (notably from new OP5 tubeless technology) remain a $9-10 million quarterly drag.
- Cost Discipline and Digitalization: Ongoing technology upgrades, including Oracle Cloud warehouse management, improved order accuracy, inventory turns, and cash conversion, supporting both margin expansion and future free cash flow potential.
The overall business remains anchored by its non-acquired revenue growth and improving operational leverage, but the diabetes segment’s muted rebound and payer mix evolution will be critical watchpoints for margin trajectory and long-term growth.
Executive Commentary
"The highlight of the quarter was continued growth in our sleep and respiratory product lines, which represent more than half of our total revenue. Building on the robust first quarter, these products grew a combined 15% year over year in the second quarter."
Richard Barish, Chairman and Interim CEO
"Our adjusted EBITDA was $171 million in the quarter, an increase of 14% compared to a year ago. This reflects an adjusted EBITDA margin of 21.6%, a full-point increase year-over-year primarily attributed to execution of our cost management program."
Jason Clemens, Chief Financial Officer
Strategic Positioning
1. Sleep and Respiratory Leadership
AdaptHealth’s investments in equipment availability, process efficiency, and resupply operations have reinforced its market leadership in sleep and respiratory, with industry data showing market share gains and robust patient demand. The company’s ability to service both new starts and resupply at scale is now a competitive differentiator, especially as supply chain constraints have eased and operational bottlenecks have been addressed.
2. Diabetes Channel Realignment
Diabetes remains a strategic priority but faces a channel and product mix reset. The company is intentionally growing its government payer book, which now accounts for 77% of CGM census, capitalizing on expanded Medicare coverage and pricing stability. However, commercial business softness and ongoing pump technology headwinds continue to weigh on growth and margin. AdaptHealth’s cross-selling initiatives and digital reorder platforms aim to enhance efficiency and patient retention, but full recovery will hinge on execution in both payer channels.
3. Value-Based Care and Humana Partnership
The July 2023 launch of a value-based HME contract with Humana covering over a million Medicare Advantage members marks a major strategic pivot. This contract, which excludes diabetes and at-home supply lines, is expected to drive incremental growth in sleep, respiratory, and HME categories. The company’s commitment to high-touch service, dedicated call centers, and expanded referral networks is intended to deepen payer relationships and set a template for future value-based arrangements.
4. Technology-Driven Efficiency
Ongoing digital transformation—including e-prescribe adoption and Oracle Cloud warehouse management—has begun to deliver measurable operational and financial benefits. These investments have reduced administrative friction, improved DSO, and enabled better inventory management, with further automation and AI-driven inventory optimization planned for 2024. The company is also consolidating sites to unlock scale and cost synergies from past acquisitions.
5. Cost Management and Operational Leverage
AdaptHealth continues to realize cost savings from its $25 million program, while ongoing review of operations is expected to yield further efficiency. Margin expansion is being driven by both revenue mix (toward higher-margin sleep/respiratory) and disciplined cost controls, positioning the company for improved free cash flow conversion in coming quarters.
Key Considerations
This quarter demonstrates AdaptHealth’s ability to drive core segment growth and operational improvements even as diabetes faces structural headwinds. The company’s pivot to value-based care, digital process upgrades, and cost discipline are critical to sustaining margin gains and long-term growth.
Key Considerations:
- Diabetes Execution Remains Pivotal: Sustained government payer growth is offsetting commercial and pump weakness, but full recovery will require improved cross-sell and channel management.
- Humana Ramp as Operational Test: The success of the Humana contract will be a key indicator of AdaptHealth’s ability to scale value-based models and deliver on service-level commitments.
- Margin Sensitivity to Product Mix: As diabetes remains lower-margin, future segment mix will influence overall profitability and cash flow.
- Technology Investments Unlocking Scale: Warehouse automation and e-prescribe are reducing cost and improving working capital, but full benefits will accrue over 2024.
- Competitive and Regulatory Backdrop: Potential reentry of Philips into the PAP market and future Medicare competitive bidding could alter pricing and margin dynamics, but management is not factoring these into near-term guidance.
Risks
Key risks include continued pressure in the diabetes segment, especially if commercial channel softness or pump headwinds persist longer than expected. Execution risk is elevated around the Humana contract ramp, which requires new infrastructure and service commitments. Regulatory shifts such as renewed Medicare competitive bidding or changes in reimbursement could impact both revenue and margin. Lastly, competitive dynamics in sleep and respiratory, particularly if supply increases or pricing competition returns, could challenge current margin structure.
Forward Outlook
For Q3 2023, AdaptHealth guided to:
- Revenue growth just over 5% year over year, with Q3 facing tougher comparables due to supply chain normalization in 2022.
- Adjusted EBITDA margin expected to remain in line with Q2 levels.
For full-year 2023, management updated guidance:
- Revenue of $3.16 to $3.20 billion
- Adjusted EBITDA of $650 to $680 million
- CapEx expected between 10% and 12% of revenue; free cash flow between 3% and 4% of revenue
Management cited several factors supporting the outlook:
- Continued strength in sleep and respiratory segments,
- Humana contract ramping through the second half,
- Ongoing cost savings and operational improvements,
- Modest growth expected in diabetes as pump headwinds persist.
Takeaways
AdaptHealth’s Q2 highlights the resilience of its core business and the importance of operational discipline as the company navigates diabetes volatility and transitions toward value-based care models.
- Core Growth Engine: Sleep and respiratory outperformance is driving both market share and margin gains, validating past investments and process improvements.
- Strategic Transformation: The Humana partnership and digital process upgrades are setting the stage for scalable, value-based growth, but execution risk remains high in the near term.
- Watch Diabetes and Margin Mix: Investors should monitor diabetes channel trends, pump headwinds, and the impact of ongoing payer mix shifts on overall profitability.
Conclusion
AdaptHealth’s Q2 demonstrated strong execution in its core segments and early success in margin expansion through disciplined cost and digital transformation. The next phase will hinge on diabetes recovery, Humana contract execution, and sustaining operational leverage as the company matures into a scaled, value-based provider.
Industry Read-Through
AdaptHealth’s results reinforce the ongoing strength in home-based sleep and respiratory care, suggesting continued demand tailwinds for device manufacturers and service providers in these categories. The company’s deliberate shift toward government payer business in diabetes highlights a broader industry trend toward payer mix management and the importance of Medicare policy in driving adoption of advanced diabetes technology. The Humana value-based contract signals increasing willingness of major payers to partner with scaled HME providers on risk-sharing models, which could accelerate industry consolidation and raise the bar for service and operational excellence. Finally, the normalization of supply chains and investments in warehouse automation are likely to become table stakes for scaled HME operators seeking to protect margin and cash flow in a more competitive and regulated landscape.